Arisan Therapeutics was founded to develop therapeutics for neglected and emerging viral diseases.
A number of these infectious diseases have the potential for significant impact on public health and have been
classified as priority biodefense-related pathogens.
Our scientific team is comprised of biologists, virologists and medicinal chemists with
extensive drug discovery and development experience. Our efforts are further supported
by a host of highly experienced collaborators and through funding from the National
Institute for Allergy and Infectious Disease.
To identify unmet medical needs and provide appropriate solutions through development, collaboration and partnerships to benefit patients with life-threatening infectious diseases.
Brian Gowen, PhD - Virology, Research Associate Professor, Utah State University
Sujan Shresta, PhD - Virology, Associate Professor, La Jolla Institute of Allergy and Immunology
Michael McCormack, MD - Pulmonology and Critical Care, Asst Professor UT Knoxville
Landon Whitby, PhD - Medicinal chemistry, The Scripps Research Institute
Justin Hoopes, PhD - Virology and clinical applications, Director of Research, AVR Labortories
Masha Sergeeva, PhD - DPMK, Principal at DMPK4Biotech